

Freedom of Information Request	FOI 22-333	29 <sup>th</sup> July 2022
--------------------------------	------------	----------------------------

**I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.**

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

• **CAPOX (Capecitabine with Oxaliplatin)**

0

• **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**

0

• **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**

0

• **Any other systemic anti-cancer therapy**

0

• **Palliative care only**

The Health Board treated <5 patients during this period.

Please note the Health Board has applied Section 40 of the Freedom of Information Act 2000. The Health Board will not provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

• **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**

0

• **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**

0

• **Nivolumab monotherapy**

0

• **Nivolumab and Ipilimumab**

0

- Any other systemic anti-cancer therapy

0

- Palliative care only

<5

**Q3. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:**

- Oesophageal cancer (any type or stage)

10

- Oesophageal adenocarcinoma (any stage)

7

- Oesophageal squamous cell carcinoma (any stage)

<5

- Gastric cancer (any type or stage)

<5

- Cancer of the gastro-oesophageal junction (any stage)

<5